5Maeda O, Ando T, Ishiguro K, et al. Safety of repeated cell-free and con- centrated ascites reinfusion therapy for malignant ascites from gastroin- testinal cancer [ J 1. Mo! Clin Onco1,2014,2 ( 6 ) : 1103-1106.
6Huang O, Lu X, Xu X, et al. Fibrin-sealant-deliveredI cisplatin chemo- therapy versus cisplatin hyperthermic intraperitoneal perfusion chemo- therapy for locally advanced gastric cancer without peritoneal metasta- ses: a randomized phase-II clinical trial with a 40-month follow-up[J]. Cell Biochem Biophys ,2015,71 ( 2 ) : 1171-1180.
7Saada E, Follana P, Peyrade F, et al. Pathogenesis arrd management of refractory malignant ascites [ J ]. Bull Cancer, 2011,98 ( 6 ) : 679 -687.
8Takeyoshi I, Makita F, lwazaki S, et al. Weekly paclitaxel in combination with doxiflaridine for peritoneally disseminated gastric cancer with ma- lignant ascites [ J ]. Anticancer Res,2011,31 ( 12 ) :4625-4630.
9Feng ZL, Chen LB, Liu ZY, et al. DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study[J]. Oncol Lett,2015,9( 1 ) :491-497.
10Thomaidis T, W6rns MA, Galle PR, et al. Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma-a report of 2 cases [ J ]. Oncol Res Treatment, 2014,37 ( t 1 ) : 674 -677.
